Topotecan

Phase 3 RAINFOL‑02 shows statistically significant and clinically meaningful PFS and OS benefits versus investigator’s choice chemotherapy in platinum‑resistant ovarian cancer.

Ris‑Rez extended median OS to 18.5 vs 10.3 months (HR 0.46) and showed improved PFS, response rates and fewer grade ≥3 TRAEs versus topotecan.

Phase III in China: Tam‑Peli halved mortality risk and sharply improved PFS and response rate versus topotecan in relapsed small‑cell lung cancer.

Phase III trial met overall survival endpoint in advanced or relapsed small‑cell lung cancer in China, with consistent secondary benefits and no new safety signals.